NATCO Pharma Reports Q2FY27 Results with Consolidated PAT at ₹202.6 Crore
Natco Pharma Ltd · Financial Result · 13 Nov 2026, 8:19 pm
NATCO Pharma Reports Q2FY27 Results with Consolidated PAT at ₹202.6 Crore NATCO Pharma reported Q2FY27 consolidated revenue from operations of ₹967.3 crore, down 29.0% YoY from ₹1,363.0 crore, largely due to lower Lenalidomide contributions despite base business growth. Consolidated net profit reached ₹202.6 crore versus ₹517.9 crore in Q2FY26. Segmentally, International Formulations generated ₹668.4 crore, Domestic Formulations rose to ₹145.7 crore, API contributed ₹61.3 crore, and Crop Health Sciences stood at ₹61.0 crore. The Board declared a second interim dividend of ₹1.25 per share (record date 19th Nov'26) and expanded its stake in Adcock Ingram to 49%.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni · 04 Nov 2026
